Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was a randomized (2:1), open-label phase 3 study in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399157/
https://www.ncbi.nlm.nih.gov/pubmed/27211272
http://dx.doi.org/10.1038/leu.2016.148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399157/
https://www.ncbi.nlm.nih.gov/pubmed/27211272
http://dx.doi.org/10.1038/leu.2016.148

Ejemplares similares